AI-Powered Single-Cell Clinical Analysis Platform

Bridging Molecular Data and
Clinical Decision-Making

AISCC is built on 10x Genomics single-cell sequencing technology and the caiSC clinical AI framework, enabling a fully automated pipeline from raw data to clinical reports and providing multi-level evidence for precision medicine.

Try Now

Trusted by leading institutions

National Genebank
Zhongshan Hospital
BGI Genomics
AI Analysis Pipeline Running

10x Genomics Single-Cell Data Parsing

Powered by caiSC Framework | Accuracy: 99.9%

Scroll down to learn more
Tech Foundation

10x Genomics Single-Cell Sequencing

High-throughput single-cell resolution precision detection cornerstone, providing high-quality multi-dimensional data input for AI analysis

Technical Principles

Using microfluidic chip and barcode labeling technology, single cells are encapsulated in droplets containing unique molecular identifiers (UMI), enabling cDNA amplification and library construction, ultimately achieving single-cell level gene expression quantification.

Single-Cell Resolution

Breaks through the bulk RNA-seq population averaging limitation, capturing cellular heterogeneity.

High-Throughput Scale

Processes thousands to tens of thousands of cells per run, suitable for batch clinical sample analysis.

Multi-Omics Compatibility

Extensible to epigenomics, immune repertoire, etc., providing multi-dimensional data input.

Clinical Application Validation

Value has been validated in dynamic monitoring of peripheral blood immune cells in COVID-19 patients, immune phenotype analysis of colorectal cancer liver metastases, etc., with data directly interfacing with AI systems for deep mining.

Core System

Intelligent Decision Engine Based on caiSC Framework

Integrates machine learning algorithms with multi-modal bioinformatics tools to build a fully automated pipeline from raw data to clinical reports

Data Preprocessing & QC Module

  • Standardized pipeline: filter low-quality cells, normalization and batch effect correction
  • Multi-dimensional QC: gene counts, UMI counts, mitochondrial gene ratio monitoring
  • Visual QC: dynamic monitoring of cell distribution via UMAP dimensionality reduction

Test data performance: qualified cell proportion 0%

Cell Type Annotation & Model Training Module

  • Machine learning integration: XGBoost classifier + marker gene feature selection
  • Independent model training: separate model for each cell type, voting mechanism for result integration
  • Dynamic database: real-time update of cell-type marker gene library

Model performance: 0 cell types average AUC reaches 1.0

Clinical Translation Module

  • Multi-modal integration: transcriptome + clinical phenotype + multi-omics cross-mapping
  • Visual decision-making: UMAP distribution, proportion heatmaps and other clinical interpretation tools
  • Precise insights: e.g., CD4+TLEPROTL1 cell proportion indicates immune response status

Core value: critical link connecting molecular data and clinical decisions

AI Model Performance Validation

AISCC Core Advantages

Accuracy Leadership

Accuracy 0.92, 3% higher than RF

Precision-Recall Balance

F1 score 0.90, unbiased

Optimal Generalization

AUC 0.97, 15% higher than LR

Strong Clinical Adaptability

Leads traditional models across all metrics

Data: benchwork comparison on preliminary test set

Report System

Standardized Clinical Analysis Report System

Standardized interpretation from single-cell data to clinical insights, providing scientific evidence for disease diagnosis, treatment, and prognosis

Quality Control Analysis

Multi-dimensional assessment of data reliability, including cell gene detection counts, UMI totals, mitochondrial gene ratios, etc., with visualization to judge sequencing quality.

Clinical Value

Ensures subsequent analysis is built upon reliable data; QC failure can indicate sample collection or experimental operation optimization directions.

Cell Type Annotation Results

Presents major cell population proportion relationships and rare cell type identification, constructing immune microenvironment molecular maps.

Clinical Relevance

Cell distribution characteristics reflect pathological mechanisms, e.g., exhausted T-cell proportion in tumor patients suggests immunotherapy resistance.

Model Training & Validation

Measures model performance through AUC, F1 score, etc., visually demonstrating reliability of each cell type annotation.

Technical Advantages

Automated standardized analysis avoids human bias, significantly shortens cycle time, suitable for batch samples and emergency scenarios.

Spatial Distribution & Function Prediction

Combines spatial transcriptome data to parse intercellular interaction networks, predicts cell functional states and differentiation trajectories.

Clinical Application

Tumor microenvironment spatial heterogeneity analysis guides biopsy site selection and treatment plan formulation.

Biomarker Screening

Based on differential expression analysis and machine learning feature selection, screens clinically significant cell subtypes and molecular markers.

Translational Value

Discovers novel diagnostic markers and therapeutic targets, accelerating translation from basic research to clinical application.

Clinical Decision Recommendations

Integrates clinical databases and literature knowledge bases, providing individualized treatment plans and prognosis assessments based on single-cell features.

Core Advantages

Provides data-supported decision references for clinicians, improving treatment precision and patient benefit rates.

Clinical Report Example Display

Standardized output format balancing research depth and clinical practicality

AISCC Single-Cell Clinical Analysis Report

Sample ID: SC20250512-008 | Analysis Date: 2025-05-13

Cell Type Distribution
Main Findings & Clinical Recommendations
  • CD8+ T-cell proportion elevated (32.7%), suggesting possible active anti-tumor immune response
  • Detected 1.2% regulatory T cells, proportion within normal range
  • Macrophages exhibit M2 polarization characteristics, consider combined immunomodulator therapy
  • Tumor-infiltrating B-cell proportion low (2.3%), may have limited response to B-cell targeted therapy
  • Recommendation: Prioritize PD-1 inhibitor therapy, perform single-cell monitoring every 3 months to assess efficacy
Analysis Tools

Professional Single-Cell Data Analysis Tool Suite

Integrates multiple bioinformatics analysis tools to meet full-process needs from basic analysis to advanced mining

Cell Clustering Analysis

Based on graph-based clustering algorithms, automatic identification and visualization of cell subpopulations

Try Now

Differential Gene Analysis

Identifies differentially expressed genes between different cell populations for functional enrichment and pathway analysis

Try Now

Cell Communication Analysis

Based on ligand-receptor interactions, parsing intercellular signal transduction networks

Try Now

Trajectory Inference

Reconstructs cell differentiation paths and developmental trajectories, revealing cell fate decision mechanisms

Try Now

Immune Repertoire Analysis

Analyzes T/B cell receptor clonal diversity and dynamic changes, evaluates immune response status

Try Now

Cell Annotation Ontology Tree

Integrates expert knowledge base of PBMC cell annotation marker genes, updated in real-time, authoritatively validated

Try Now

Cell Annotation Library Statistics

Validates PBMC cell annotation files through interactive charts, enabling statistical analysis and format conversion

Try Now

Custom Analysis Pipeline

Drag-and-drop workflow builder, supporting personalized analysis design and automated execution

Try Now

Tool Usage Workflow

Data Upload & Format Validation

Supports 10x Genomics standard format and multiple single-cell sequencing data formats, automatically verifies data integrity and format correctness

1
  • • Supports .h5, .mtx, .csv, .tsv formats
  • • Max 20GB single file upload
  • • Auto-detects data integrity
  • • 10+ preset standard analysis pipelines
  • • Supports parameter customization
  • • Visual workflow design interface
2

Analysis Pipeline Selection & Configuration

Choose preset analysis pipelines or customize analysis steps, configure key parameters, system automatically optimizes analysis strategy

Automated Analysis & Real-Time Monitoring

Cloud high-performance computing cluster executes analysis tasks, real-time displays analysis progress and intermediate results, supports breakpoint continuation

3
  • • Distributed computing acceleration
  • • Real-time progress visualization
  • • Email/SMS result notifications
  • • Interactive visual reports
  • • Multiple format export support
  • • Result sharing & collaboration
4

Result Visualization & Export

Generates interactive visual reports, supports multiple format exports, provides result interpretation and clinical recommendations

Future Outlook

LLM Agents: Revolutionizing Single-Cell Clinical Analysis

Integrating multi-model consensus and domain knowledge enhancement, building the next-generation intelligent platform for "fully automated analysis + cross-scenario interpretation + precision diagnostic assistance"

Three Future Core Application Scenarios

Precision Annotation: Reference-Free Typing

Pain Point: Traditional methods rely on human references, rare cell recognition rate <60%

Future Capability: LLM agent automatically executes "clustering→DEG screening→literature validation" full pipeline, multi-model consensus error correction, accuracy rate reaches 92%.

Report Interpretation: Dual-Perspective Translation

Pain Point: Raw results are poorly readable, interpretation takes 4-6 hours

Future Capability: Automatically generates research-compliant reports and clinical language translation (e.g., "CD8+T proportion"→"indicates potential immune therapy benefit"), visual interpretation accuracy rate 85%.

Clinical Application: Diagnostic Assistance

Pain Point: Difficulty in integrating multi-dimensional data, low treatment plan matching efficiency

Future Capability: Integrates single-cell + imaging + medical history, intelligently types tumor microenvironment, dynamically monitors treatment efficacy, clinical guideline alignment rate 93%.

Future LLM Scheme Performance Advantages

AISCC Fusion Scheme

Annotation Accuracy

92%, 6-22% higher than single model

Hallucination Rate

As low as 4%, high clinical credibility

Cost

60% lower than pure GPT scheme

LLM Agent Implementation Roadmap

Phase 1: Core Module Deployment

Prioritize the deployment of the "reference-free annotation module" (technological maturity already verified) to meet the rapid typing needs of research

1

Objective: Adapt to 10+ common tissue types within 3 months, accuracy rate ≥90%

Objective: Integrate CellMarker 2.0 + Pathway Commons, increase knowledge coverage by 50%

2

Phase 2: Knowledge Tool Expansion

Connect to authoritative biological databases and clinical guideline libraries, reinforce knowledge accuracy through RAG mechanism

Phase 3: Division of Labor Framework

Develop "annotation agent + interpretation agent + review agent", break down tasks to reduce single model pressure

3

Objective: Reduce hallucination rate to below 3%, ensure 100% evidence level of clinical recommendations

Objective: Collaborate with 50+ medical institutions, accumulate 10000+ clinical annotated data

4

Phase 4: Open Ecosystem Building

Open API interfaces, support third-party tool integration, build single-cell LLM application ecosystem

Book an LLM Agent Closed Beta Experience

Be the first to experience core capabilities such as reference-free cell typing and dual-perspective report interpretation, empowering precision medicine research and clinical translation

Book Now
About System

AI Single-Cell Clinical Analysis System

An innovative platform connecting single-cell sequencing technology with clinical applications, empowering precision medicine development

System Introduction

The AI Single-Cell Clinical Analysis System (AISCC) is an integrated analysis platform built on 10x Genomics single-cell sequencing technology and the proprietary caiSC clinical AI framework. The system integrates machine learning, bioinformatics, and clinical knowledge bases to achieve fully automated analysis from raw sequencing data to clinical decision-making suggestions.

Core Advantages

High-Efficiency Automation

Fully automated analysis pipeline, generating clinical reports from raw data in just 3 hours, significantly reducing the traditional 3-7 day analysis cycle

High-Precision Analysis

AI models optimized with large-scale training datasets, achieving 99.9% cell type annotation accuracy, supporting identification of 93 immune and tumor cell subtypes

Clinically Oriented Design

The reporting system balances scientific depth and clinical relevance, providing evidence-based treatment recommendations and prognostic assessments

Application Scenarios

Tumor Immune Microenvironment Analysis Autoimmune Disease Research Infectious Disease Immune Response Stem Cell Differentiation Research Drug Response Prediction Transplant Rejection Monitoring

Partnership with Medical Institutions

4

Completed Analysis Cases

374

AISCC System Architecture

Contact Us & Collaboration Inquiry

Whether you are a medical institution, research unit, or enterprise, we look forward to partnering with you to advance the clinical application of single-cell technology

Email

service@hiplot.com.cn

Send Email

Phone Consultation

021-60190682

Call Now

Address

Room 406, Building 1, Yuanxiang Lake, No. 2641 HuYi Road, Jiading District, Shanghai

View Map